ACADIA Pharmaceuticals’ (ACAD) “Overweight” Rating Reiterated at Cantor Fitzgerald

ACADIA Pharmaceuticals (NASDAQ:ACAD)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a research note issued on Thursday,Benzinga reports. They currently have a $28.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 42.86% from the company’s previous close. Cantor Fitzgerald also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.15 EPS.

Several other analysts also recently weighed in on ACAD. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday. Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. Finally, StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Trading Up 1.3 %

NASDAQ:ACAD opened at $19.60 on Thursday. The company has a market capitalization of $3.26 billion, a P/E ratio of 25.13 and a beta of 0.37. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $24.53. The firm has a fifty day simple moving average of $18.37 and a 200-day simple moving average of $16.81.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Virtus Fund Advisers LLC acquired a new position in ACADIA Pharmaceuticals in the 4th quarter worth about $39,000. R Squared Ltd purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $47,000. GF Fund Management CO. LTD. purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $64,000. Quest Partners LLC raised its stake in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares during the period. Finally, KBC Group NV lifted its position in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.